DNA methylation and HDAC inhibitors
| Target/drugs . |
|---|
| DNA methylation |
| Nucleoside analog inhibitors |
| 5-Azacytidine6,22,65 |
| 5-Aza-2′-deoxycytidine (Decitabine)4,6,39,69 |
| Zebularine102 |
| 5-fluoro-2′-deoxycytidine (FCDR)103 |
| Non-nucleoside analog inhibitors |
| Procainamide4,22,99 |
| Hydralazine4 |
| Procaine104 |
| Epigallocatechin-3-gallate (EGCG)100 |
| N-Phthalyl-L-tryptophan (RG108)4 |
| Antisense oligonucleotides |
| DNMT1 ASO101 |
| HDAC inhibitors |
| Hydroxamates |
| Trichostatin A87 |
| Suberoylanilide hydroxamic acid (Vorinostat; SAHA)105 |
| Oxamflatin106 |
| Scriptaid107 |
| Pyroxamide108 |
| M-carboxycinnamic acid bishydroxamide (CBHA)109 |
| Cyclic tetrapeptides |
| Desipeptide (FK228)110 |
| Apicidin111 |
| Trapoxin-A and trapoxin B112 |
| Aliphatic acids |
| Valproic acid113 |
| Phenyl butyrate114 |
| Benzamides |
| MS-275115 |
| N-acetyldinaline (CI-994)115 |
| Electrophilic ketones |
| Trifluoromethyl ketones116 |
| α-Ketoamides |
| Miscellaneous compounds |
| Depudecin117 |
| Target/drugs . |
|---|
| DNA methylation |
| Nucleoside analog inhibitors |
| 5-Azacytidine6,22,65 |
| 5-Aza-2′-deoxycytidine (Decitabine)4,6,39,69 |
| Zebularine102 |
| 5-fluoro-2′-deoxycytidine (FCDR)103 |
| Non-nucleoside analog inhibitors |
| Procainamide4,22,99 |
| Hydralazine4 |
| Procaine104 |
| Epigallocatechin-3-gallate (EGCG)100 |
| N-Phthalyl-L-tryptophan (RG108)4 |
| Antisense oligonucleotides |
| DNMT1 ASO101 |
| HDAC inhibitors |
| Hydroxamates |
| Trichostatin A87 |
| Suberoylanilide hydroxamic acid (Vorinostat; SAHA)105 |
| Oxamflatin106 |
| Scriptaid107 |
| Pyroxamide108 |
| M-carboxycinnamic acid bishydroxamide (CBHA)109 |
| Cyclic tetrapeptides |
| Desipeptide (FK228)110 |
| Apicidin111 |
| Trapoxin-A and trapoxin B112 |
| Aliphatic acids |
| Valproic acid113 |
| Phenyl butyrate114 |
| Benzamides |
| MS-275115 |
| N-acetyldinaline (CI-994)115 |
| Electrophilic ketones |
| Trifluoromethyl ketones116 |
| α-Ketoamides |
| Miscellaneous compounds |
| Depudecin117 |